Cengild Medical Bhd's EBIT per Share for the
three
months ended in Mar. 2026 was RM0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was RM0.02.
During the past 12 months, the average EBIT per Share Growth Rate of Cengild Medical Bhd was -28.60% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 9.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Cengild Medical Bhd's EBIT per Share or its related term are showing as below:
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Cengild Medical Bhd was 65.10% per year. The lowest was -3.90% per year. And the median was 13.00% per year.
XKLS:0243's 3-Year EBIT Growth Rate is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 12 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Cengild Medical Bhd (XKLS:0243) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Cengild Medical Bhd EBIT per Share Related Terms
Cengild Medical Bhd EBIT per Share Historical Data
* Premium members only.
The historical data trend for Cengild Medical Bhd's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cengild Medical Bhd (XKLS:0243) has a EBIT per Share of RM0.02 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Cengild Medical Bhd and its competitors. According to the industry distribution chart, Cengild Medical Bhd ranks #999999 out of 528 companies in the Healthcare Providers & Services industry.
Is Cengild Medical Bhd's EBIT per Share too high?
Cengild Medical Bhd's current EBIT per Share is RM0.02. Based on the distribution chart, Cengild Medical Bhd ranks #999999 out of 528 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Cengild Medical Bhd has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cengild Medical Bhd's EBIT per Share compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Cengild Medical Bhd ranks #999999 out of 528 companies for EBIT per Share. This places Cengild Medical Bhd in the lower half of its industry. The industry median EBIT per Share is 12.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 12.00, based on 528 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Cengild Medical Bhd and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 12.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cengild Medical Bhd's current EBIT per Share is RM0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cengild Medical Bhd stock overvalued right now?
Based on GuruFocus' analysis, Cengild Medical Bhd (XKLS:0243) is currently considered Significantly Undervalued. The stock's GF Value™ is RM0.29, compared to a current price of RM0.20 — trading 32.8% below its estimated fair value. The current EBIT per Share is RM0.02. Cengild Medical Bhd's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Cengild Medical Bhd (XKLS:0243), the current EBIT per Share is RM0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cengild Medical Bhd (XKLS:0243) Overvalued in 2026?
Based on GuruFocus' analysis, Cengild Medical Bhd stock appears to be undervalued.
The current stock price of RM0.20 is trading 32.8% below its estimated GF Value™ of RM0.29.
GuruFocus considers Cengild Medical Bhd to be Significantly Undervalued.
Key valuation signals for XKLS:0243:
EBIT per Share: RM0.02
GF Value™: RM0.29 vs. price of RM0.20 (32.8% below fair value)
No single metric tells the full story. See the XKLS:0243 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cengild Medical Bhd is a healthcare service provider operating a medical centre specializing in the diagnosis and treatment of gastrointestinal-related diseases, oncology, gynecology services., liver diseases, and obesity. The company operates in Malaysia and has two reportable segments, Consultant Services and Medical Management Services. A substantial portion of the overall revenue is generated from its Medical Management Services segment.
66GF Score
Get the complete analysis for XKLS:0243
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0243 has been successfully added to your 
